Compare TLS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | CABA |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.1M | 319.6M |
| IPO Year | 2020 | 2019 |
| Metric | TLS | CABA |
|---|---|---|
| Price | $4.44 | $3.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $7.90 | ★ $14.50 |
| AVG Volume (30 Days) | 680.8K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.51 | 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $164,805,000.00 | N/A |
| Revenue This Year | $18.72 | N/A |
| Revenue Next Year | $14.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 52.21 | N/A |
| 52 Week Low | $1.83 | $1.06 |
| 52 Week High | $8.36 | $3.78 |
| Indicator | TLS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 63.99 |
| Support Level | $3.80 | $2.32 |
| Resistance Level | $4.61 | $3.73 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 85.25 | 99.48 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.